The 2023 European Society of Hypertension (ESH) and 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines both emphasize proper blood pressure (BP) ...

Christopher M. Kramer, MD, FACC, received his medical degree from the University of California, San Francisco School of Medicine, and completed his residency and chief residency in internal medicine, ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

I am honored to serve as the new Chair of this dynamic community, and I am excited to work alongside all of you. As cardiovascular professionals dedicated to advancing our field, our collective ...

Patients with heart failure (HF) who had an interatrial shunt inserted did not see any significant benefits overall, compared with those who underwent a placebo procedure, after a median 22-month ...

The Acute Coronary Syndromes Clinical Topic Collection gathers the latest guidelines, news, JACC articles, education, meetings and clinical images pertaining to its cardiovascular topical area — all ...

In this week’s View, Dr. Eagle looks at the new ACC/AHA guideline for prevention, detection, evaluation and management of high blood pressure (BP). He then discusses new-onset right bundle branch ...

The 2025 ACC/AHA Acute Coronary Syndrome (ACS) Guideline clarifies diagnostic distinctions using electrocardiogram changes, troponin levels, and imaging tools such as coronary CT angiography and ...

Access ACC guidelines and clinical policy documents as well as related resources ...

More time spent sitting, reclining or lying down during the day may increase the risk of cardiovascular disease (CVD) and death, according to a study in JACC, the flagship journal of the American ...

Every week, ACC will continue to post new ACCEL content on the ACCEL Lite podcast.

The U.S. Food and Drug Administration (FDA) has approved finerenone to treat patients with heart failure (HF) with LVEF ≥40%. The approval was based on results from the FINEARTS-HF trial, presented at ...